PER-042-06
Completed
未知
PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUPS, MULTINATIONAL, TELAVANCIN INTRAVENOUS VERSUS VANCOMYCIN FOR THE TREATMENT OF INTRA-HOSPITALARY PNEUMONIA WITH EMPHASIS IN PATIENTS WITH INFECTIONS DUE TO STAPHYLOCOCCUS AUREUS METHICILLIN RESISTENT
THERAVANCE INC (OMNICARE CLINICAL RESEARCH),0 sites0 target enrollmentJuly 31, 2006
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- THERAVANCE INC (OMNICARE CLINICAL RESEARCH),
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Men and women ≥ 18 years of age.
- •2\. Clinical signs and symptoms compatible with acquired pneumonia after at least 48 hours of continuous stay in an acute or chronic care hospital, or acquired within 7 days after being discharged after hospitalization of ≥ 3 days of duration.
- •3\. Chest x\-ray with results compatible with a diagnosis of pneumonia within 48 hours prior to randomization in the study.
- •4\. Availability of respiratory or sputum specimens appropriate for Gram stain and culture, and venous access for IV dosing.
- •5\. Willingness to receive intravenous treatment throughout the treatment.
- •6\. Patients from whom informed consent can be obtained to participate in the study, as defined by the Teaching and Research Committee or the Ethics Committee.
Exclusion Criteria
- •1\. Patient who received more than 24 hours of systemic antibiotic treatment potentially effective for Gram\-positive pneumonia immediately before randomization.
- •2\. Respiratory tract or sputum samples with only Gram negative bacteria in Gram stain or culture.
- •3\. Patient with confirmed MSSA or S. pneumoniae infection and who will require more than 24 hours of concomitant treatment of the study medication with an antibiotic for coverage against Gram\-negative that has activity against MSSA or S. pneumoniae.
- •4\. Suspicion or confirmation of pulmonary disease that does not allow to evaluate the therapeutic response, cystic fibrosis or active tuberculosis.
- •5\. Suspicion or confirmation of pneumonia due to Legionella pneumophila.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A CLINICAL STUDY TO TEST HOW EFFECTIVE AND SAFE GLPG1690 (G451990) IS FOR SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) WHEN USED TOGETHER WITH STANDARD MEDICAL TREATMENT.-J841 Other interstitial pulmonary diseases with fibrosisOther interstitial pulmonary diseases with fibrosisJ841PER-001-19Galapagos N.V,21
Active, not recruiting
Phase 1
BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous UrticariaEUCTR2022-001745-20-BGCuraTeQ Biologics Private Ltd.600
Active, not recruiting
Not Applicable
A phase 3 Randomized, Double-blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of venous thromboembolism in acutely III medical subjects during and following hospitalization. - ADOPTTotal Venous thromboembolism (VTE), defined as the combination of fatal or nonfatal pulmonary embolism, symptomatic deep vein thrombosis (DVT), and asymptomatic proximal DVTMedDRA version: 9.1Level: LLTClassification code 10043566Term: ThromboembolismEUCTR2006-003674-96-ITBristol Myers Squibb International Corporation7,502
Not yet recruiting
Phase 3
A clinical trial study to assess the efficacy and safety of Granexin Gel in the treatment of Diabetic Foot UlcerHealth Condition 1: E118- Type 2 diabetes mellitus with unspecified complicationsCTRI/2018/10/015923FirstString Research Inc
Completed
Not Applicable
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness ADOPTI809-I809 Phlebitis and thrombophlebitis of unspecified sitePhlebitis and thrombophlebitis of unspecified sitePER-119-08BRISTOL MYERS SQUIBB PERU S.A.,112